Podcast Highlights

New Developments in Tetracycline-Class Antibiotics

By December 21, 2020No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

New Developments in Tetracycline-class Antibiotics

Dr. Christopher Bunick & Dr. Adam Friedman

 

Tetracycline antibiotics are like the Snickers of dermatology. Instead of “Hungry? Grab a Snickers,” “Acne? Grab a tetracycline…” for months even though this goes against clinical guidelines and concerns regarding antimicrobial resistance (woof, thats a mouthful for a slogan). Like a Snickers, they fulfill a need, they’re good for a whole lot, but too much, not so good. We have seen some evolution in maximizing the clinical benefits of our therapeutic Snickers, such as subantimicrobial dosing, but more innovation is needed to get the most anti-inflammatory bang for our buck. Enter the concept of narrow spectrum antibiotics and sarecycline.

 Join host Dr. Adam Friedman on an investigative journey detailing how antibiotic structure and function can meet to yield novel properties with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and captain of crystallography and cryo-electron microscopy. Hear first hand how a simple idea morphed into a groundbreaking program. Complete your understanding of how antibiotics can be anti-inflammatory. Love the new narrow spectrum lexicon (or try at least).

Listen Now
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Learning Objectives
Upon completion of this podcast, learners should be able to:
  • Summarize the mechanism of action of tetracycline antibiotics and their role in acne
  • Define narrow spectrum antibiotic, and understand the clinical translation.

Disclosures

 

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Christopher Bunick, MD, PhD – Grant/Research: Almirall, Consultant: Almirall, Speakers’ Bureau: Almirall

You May Also Like

Insights On the Pediatric, Adolescent & Adult AD Patient

| Atopic Dermatitis, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Dr. Peter Lio, Dr. Lindsay Finklea & Dr. Adam Friedman   You can't truly understand someone until you walk a mile in their shoes. This…

New Developments in Tetracycline-Class Antibiotics

| Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Dr. Christopher Bunick & Dr. Adam Friedman   Tetracycline antibiotics are like the Snickers of dermatology. Instead of "Hungry? Grab a Snickers," "Acne? Grab a…

Current Understanding of the Pathophysiology, Etiology, Prevalence & Burden of AD

| Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Dr. Peter Lio and Dr. Adam Friedman   In part 2 of this 5 part podcast homage to Atopic Dermatitis, JDD Podcast host Dr. Adam…